AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange
ZURICH, Aug. 5, 2025 -- The Adecco Group Half Year Report 2025 is now available in the Ad Hoc section of the Group's website, which is directly accessible by clicking here.
Contact: investor.relations@adeccogroup.com
View original content:https://www.prnewswire.co.uk/news-releases/the-adecco-group-half-year-report-2025-302521046.html
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.
Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027 or first quarter of 2028 Cash and cash equivalents of approximately $456.2 million as of September 30, 2026, expected to fund operations into 2029 WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”)
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 and provided an update on recent corporate progress. On August 10, 2026, Tenax announced that LEVEL, the
Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting interim data in the second half of 2027 Achieved best-in-class preclinical data with SERPINA1 mRNA editing (>95%) with KRRO-111 Planned regulatory submission in the first half of 2027 Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash run
Total ARR of $357.6 Million, an Increase of 0.5% Versus Prior Year. GMV of $9.0 Billion, an Increase of 14% Versus Prior Year. Operating Cash Flow of $9.4 Million. AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Commerce.com, Inc. (Nasdaq: CMRC), the open commerce ecosystem built to help merchants win as AI reshapes how customers discover and buy, today announced financial results for its third quarter ended September 30, 2026. “Our third quarter results reflect another period of disciplined ex
Revenue of $153 million; Clinical Subscription Revenue of $38 million, up 48% year-over-year 2.3 million Total End of Period Subscribers; 40% year-over-year Clinical End of Period Subscriber growth to 174 thousand and 16% year-over-year Core+ End of Period Subscriber growth to 546 thousand Positive Net Income of $15.1 million, representing a 9.9% Net Income Margin; Adjusted EBITDA 1 of $51.7 million, representing a 33.8% Adjusted EBITDA Margin 1 NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- WW Int
Reported total revenue of $14.0 million in the third quarter of 2026 driven by 17% growth in the Surgical Aesthetics segment Initiated successful full commercial launch of the power liposuction handpiece for the AYON system in the third quarter Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million Management to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Comp
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marex Group Limited (‘Marex’ or the ‘Group’; Nasdaq: MRX) a diversified global financial services platform providing market access, infrastructure services and essential liquidity to clients across commodities and financial markets, today reported the Group’s preliminary unaudited financial results for the third quarter ('Q3 2026'). Ian Lowitt, Group Chief Executive Officer, stated, “Marex delivered another record performance in the third quarter, with
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Zipline today announced a $1.5 billion raise at a $21.5 billion post-money valuation, led by Paradigm, WCM Investment Management, and Layer Global with participation from Valor Equity Partners, Fidelity Management & Research Company, Uber, Tiger Global, J.P. Morgan, ARK Invest, and Salesforce Ventures. Zipline will use the capital to expand its U.S. manufacturing facilities and ramp hiring as it builds a nationwide drone delivery net
Comments (0)
Login to join the conversation
Login / RegisterNo comments yet. Be the first to comment!